• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Male Breast Cancer Market

    ID: MRFR/Pharma/5043-HCR
    100 Pages
    Rahul Gotadki
    September 2025

    Global Male Breast Cancer Market Research Report Information By Type (Infiltrating Ductal Carcinoma, Inflammatory Breast Cancer, Paget Disease, Ductal Carcinoma), by Diagnosis (Mammography, Biopsy, Pet Scan, Others), by Treatment (Local, Systemic) – Forecast Till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Male Breast Cancer Market Research Report – Forecast to 2032 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Male Breast Cancer Market Summary

    The Global Male Breast Cancer Market is projected to grow significantly from 1.82 USD Billion in 2024 to 4.57 USD Billion by 2035.

    Key Market Trends & Highlights

    Male Breast Cancer Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 8.73% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 4.57 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 1.82 USD Billion, reflecting the current demand for male breast cancer treatments.
    • Growing adoption of innovative treatment options due to increasing awareness of male breast cancer is a major market driver.

    Market Size & Forecast

    2024 Market Size 1.82 (USD Billion)
    2035 Market Size 4.57 (USD Billion)
    CAGR (2025-2035) 8.73%

    Major Players

    Achieve Life Sciences, Inc., Pfizer, Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Sanofi, Novartis AG, BioNumerik Pharmaceuticals Inc., Seattle Genetics, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca, Accord Healthcare, Bayer AG

    Male Breast Cancer Market Drivers

    Rising Incidence Rates

    The Global Male Breast Cancer Market Industry is experiencing growth due to rising incidence rates of male breast cancer. Although it remains a rare condition, the increasing number of diagnosed cases has garnered attention from healthcare providers and researchers. Factors such as genetic predisposition and lifestyle changes may contribute to this trend. As more men are diagnosed, the demand for treatment and support services is likely to increase, thereby expanding the market. This trend underscores the necessity for ongoing research and development in the field, as well as the importance of tailored healthcare strategies.

    Market Growth Projections

    The Global Male Breast Cancer Market Industry is poised for substantial growth, with projections indicating a market size of 1.82 USD Billion in 2024 and an anticipated increase to 4.57 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 8.73% from 2025 to 2035. Factors contributing to this expansion include rising awareness, advancements in treatment options, and supportive government policies. As the market continues to evolve, stakeholders are likely to focus on innovative solutions to address the unique challenges associated with male breast cancer.

    Supportive Government Policies

    Supportive government policies play a pivotal role in shaping the Global Male Breast Cancer Market Industry. Governments worldwide are increasingly recognizing the need for funding research and awareness programs related to male breast cancer. Initiatives aimed at improving access to screening and treatment options are being implemented, which can enhance early detection and reduce mortality rates. For instance, some countries have introduced subsidized healthcare programs that cover the costs of treatment for male breast cancer patients. Such policies are likely to foster market growth and improve patient outcomes in the coming years.

    Advancements in Treatment Options

    Innovations in treatment modalities are significantly influencing the Global Male Breast Cancer Market Industry. The development of targeted therapies and personalized medicine has improved treatment outcomes for male patients. For example, the introduction of new hormonal therapies and chemotherapy regimens has shown promising results in clinical trials. These advancements not only enhance survival rates but also improve the quality of life for patients. As these treatment options become more widely available, they are expected to drive market growth, with projections indicating a market size of 4.57 USD Billion by 2035.

    Increasing Awareness and Education

    The Global Male Breast Cancer Market Industry is witnessing a surge in awareness and education initiatives aimed at both healthcare professionals and the general public. Campaigns focusing on the importance of early detection and understanding risk factors are crucial. For instance, organizations are increasingly utilizing social media platforms to disseminate information, which has been shown to enhance knowledge about male breast cancer. This heightened awareness is likely to lead to earlier diagnosis and treatment, contributing to the overall growth of the market. As awareness continues to rise, the market is projected to reach 1.82 USD Billion in 2024.

    Growing Research and Development Investments

    Investments in research and development are crucial for the advancement of the Global Male Breast Cancer Market Industry. Pharmaceutical companies and research institutions are focusing on understanding the biological mechanisms of male breast cancer, which may lead to the discovery of novel therapeutic targets. Increased funding for clinical trials and innovative treatment approaches is expected to yield new therapies that can effectively combat the disease. As the market evolves, the compound annual growth rate (CAGR) is projected to be 8.73% from 2025 to 2035, reflecting the potential for significant advancements in treatment options.

    Key Companies in the Male Breast Cancer Market market include

    Future Outlook

    Male Breast Cancer Market Future Outlook

    The Global Male Breast Cancer Market is projected to grow at 8.73% CAGR from 2024 to 2035, driven by increasing awareness, advancements in treatment options, and improved diagnostic technologies.

    New opportunities lie in:

    • Develop targeted therapies focusing on genetic mutations prevalent in male breast cancer.
    • Invest in telemedicine solutions for remote consultations and follow-ups.
    • Enhance awareness campaigns tailored to male populations to increase early detection rates.

    By 2035, the market is expected to demonstrate robust growth, reflecting heightened awareness and improved treatment modalities.

    Market Segmentation

    BY Treatment

    • Lymph Nodes Biopsy 
    • Breast-Conserving Surgery
    • Mastectomy
    • Surgery
    • Local Treatments
    • Orchiectomy (Castration)
    • Using Drugs
    • Hormone Therapy
    • Neoadjuvant Therapy
    • Adjuvant Therapy
    • Chemotherapy
    • Systemic Treatments
    • Radiation Therapy
    • For Cancer with BRCA Mutations
    • For Hormone Receptor Positive Breast Cancer
    • For HER2 Positive Breast Cancer
    • Targeted Therapy
    • Americas
    • South America
    • Canada
    • US
    • North America
    • Europe
    • Eastern Europe
    • Rest of Western Europe
    • UK
    • Spain
    • Italy
    • France
    • Germany
    • Western Europe
    • Asia-Pacific
    • Rest of Asia-Pacific
    • South Korea
    • Australia
    • India
    • China
    • Japan
    • Africa
    • Middle East
    • Middle East & Africa
    • Academic medical institutes and universities
    • Medical research laboratories
    • Market research and consulting service providers
    • Government and independent regulatory authorities
    • Government and independent research laboratories
    • Research and Development (R&D) Companies
    • Breast cancer drug suppliers
    • Breast cancer drug manufacturers

    Intended Audience

    • Academic medical institutes and universities
    • Medical research laboratories
    • Market research and consulting service providers
    • Government and independent regulatory authorities
    • Government and independent research laboratories
    • Research and Development (R&D) Companies
    • Breast cancer drug suppliers
    • Breast cancer drug manufacturers

    Male Breast Cancer Market, by Type

    • Infiltrating Ductal carcinoma
    • Inflammatory Breast Cancer
    • Paget’s Disease of the Nipple
    • Ductal Carcinoma in Situ
    • Other Tests
    • MRI Scan
    • CT Scan
    • PET Scan
    • Excisional Biopsy
    • Core Biopsy
    • Fine Needle Aspiration Biopsy
    • Biopsy
    • Mammography
    • Lymph Nodes Biopsy 
    • Breast-Conserving Surgery
    • Mastectomy
    • Surgery
    • Local Treatments
    • Orchiectomy (Castration)
    • Using Drugs
    • Hormone Therapy
    • Neoadjuvant Therapy
    • Adjuvant Therapy
    • Chemotherapy
    • Systemic Treatments
    • Radiation Therapy
    • For Cancer with BRCA Mutations
    • For Hormone Receptor Positive Breast Cancer
    • For HER2 Positive Breast Cancer
    • Targeted Therapy
    • Americas
    • South America
    • Canada
    • US
    • North America
    • Europe
    • Eastern Europe
    • Rest of Western Europe
    • UK
    • Spain
    • Italy
    • France
    • Germany
    • Western Europe
    • Asia-Pacific
    • Rest of Asia-Pacific
    • South Korea
    • Australia
    • India
    • China
    • Japan
    • Africa
    • Middle East
    • Middle East & Africa
    • Academic medical institutes and universities
    • Medical research laboratories
    • Market research and consulting service providers
    • Government and independent regulatory authorities
    • Government and independent research laboratories
    • Research and Development (R&D) Companies
    • Breast cancer drug suppliers
    • Breast cancer drug manufacturers

    Male Breast Cancer Market, by Region

    • Americas
    • South America
    • Canada
    • US
    • North America
    • Europe
    • Eastern Europe
    • Rest of Western Europe
    • UK
    • Spain
    • Italy
    • France
    • Germany
    • Western Europe
    • Asia-Pacific
    • Rest of Asia-Pacific
    • South Korea
    • Australia
    • India
    • China
    • Japan
    • Africa
    • Middle East
    • Middle East & Africa
    • Academic medical institutes and universities
    • Medical research laboratories
    • Market research and consulting service providers
    • Government and independent regulatory authorities
    • Government and independent research laboratories
    • Research and Development (R&D) Companies
    • Breast cancer drug suppliers
    • Breast cancer drug manufacturers

    Male Breast Cancer Market Key Players

    • Bayer AG 
    • Accord Healthcare
    • AstraZeneca
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc.
    • Seattle Genetics, Inc.
    • BioNumerik Pharmaceuticals Inc.
    • Novartis AG
    • Sanofi
    • F. Hoffmann-La Roche
    • Bristol-Myers Squibb Company
    • Pfizer, Eli Lilly and Company
    • Achieve Life Sciences, Inc.

    Male Breast Cancer Market, by Diagnosis

    • Other Tests
    • MRI Scan
    • CT Scan
    • PET Scan
    • Excisional Biopsy
    • Core Biopsy
    • Fine Needle Aspiration Biopsy
    • Biopsy
    • Mammography
    • Lymph Nodes Biopsy 
    • Breast-Conserving Surgery
    • Mastectomy
    • Surgery
    • Local Treatments
    • Orchiectomy (Castration)
    • Using Drugs
    • Hormone Therapy
    • Neoadjuvant Therapy
    • Adjuvant Therapy
    • Chemotherapy
    • Systemic Treatments
    • Radiation Therapy
    • For Cancer with BRCA Mutations
    • For Hormone Receptor Positive Breast Cancer
    • For HER2 Positive Breast Cancer
    • Targeted Therapy
    • Americas
    • South America
    • Canada
    • US
    • North America
    • Europe
    • Eastern Europe
    • Rest of Western Europe
    • UK
    • Spain
    • Italy
    • France
    • Germany
    • Western Europe
    • Asia-Pacific
    • Rest of Asia-Pacific
    • South Korea
    • Australia
    • India
    • China
    • Japan
    • Africa
    • Middle East
    • Middle East & Africa
    • Academic medical institutes and universities
    • Medical research laboratories
    • Market research and consulting service providers
    • Government and independent regulatory authorities
    • Government and independent research laboratories
    • Research and Development (R&D) Companies
    • Breast cancer drug suppliers
    • Breast cancer drug manufacturers

    Male Breast Cancer Market, by Treatment

    • Lymph Nodes Biopsy 
    • Breast-Conserving Surgery
    • Mastectomy
    • Surgery
    • Local Treatments
    • Orchiectomy (Castration)
    • Using Drugs
    • Hormone Therapy
    • Neoadjuvant Therapy
    • Adjuvant Therapy
    • Chemotherapy
    • Systemic Treatments
    • Radiation Therapy
    • For Cancer with BRCA Mutations
    • For Hormone Receptor Positive Breast Cancer
    • For HER2 Positive Breast Cancer
    • Targeted Therapy
    • Americas
    • South America
    • Canada
    • US
    • North America
    • Europe
    • Eastern Europe
    • Rest of Western Europe
    • UK
    • Spain
    • Italy
    • France
    • Germany
    • Western Europe
    • Asia-Pacific
    • Rest of Asia-Pacific
    • South Korea
    • Australia
    • India
    • China
    • Japan
    • Africa
    • Middle East
    • Middle East & Africa
    • Academic medical institutes and universities
    • Medical research laboratories
    • Market research and consulting service providers
    • Government and independent regulatory authorities
    • Government and independent research laboratories
    • Research and Development (R&D) Companies
    • Breast cancer drug suppliers
    • Breast cancer drug manufacturers

    Male Breast Cancer Market Regional Analysis

    • Infiltrating Ductal carcinoma
    • Inflammatory Breast Cancer
    • Paget’s Disease of the Nipple
    • Ductal Carcinoma in Situ
    • Other Tests
    • MRI Scan
    • CT Scan
    • PET Scan
    • Excisional Biopsy
    • Core Biopsy
    • Fine Needle Aspiration Biopsy
    • Biopsy
    • Mammography
    • Lymph Nodes Biopsy 
    • Breast-Conserving Surgery
    • Mastectomy
    • Surgery
    • Local Treatments
    • Orchiectomy (Castration)
    • Using Drugs
    • Hormone Therapy
    • Neoadjuvant Therapy
    • Adjuvant Therapy
    • Chemotherapy
    • Systemic Treatments
    • Radiation Therapy
    • For Cancer with BRCA Mutations
    • For Hormone Receptor Positive Breast Cancer
    • For HER2 Positive Breast Cancer
    • Targeted Therapy
    • Americas
    • South America
    • Canada
    • US
    • North America
    • Europe
    • Eastern Europe
    • Rest of Western Europe
    • UK
    • Spain
    • Italy
    • France
    • Germany
    • Western Europe
    • Asia-Pacific
    • Rest of Asia-Pacific
    • South Korea
    • Australia
    • India
    • China
    • Japan
    • Africa
    • Middle East
    • Middle East & Africa
    • Academic medical institutes and universities
    • Medical research laboratories
    • Market research and consulting service providers
    • Government and independent regulatory authorities
    • Government and independent research laboratories
    • Research and Development (R&D) Companies
    • Breast cancer drug suppliers
    • Breast cancer drug manufacturers

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 1.43 (USD Billion)
    Market Size 2024 1.82 (USD Billion)
    Market Size 2032 4.03 (USD Billion)
    Compound Annual Growth Rate (CAGR) 4.27 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
    Geographies Covered America, Europe, Asia Pacific, Middle East and Africa
    Key Vendors Achieve Life Sciences, Inc., Pfizer, Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Sanofi, Novartis AG, BioNumerik Pharmaceuticals Inc., Seattle Genetics, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca, Accord Healthcare, and Bayer AG

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    Which region is expected to lead the Male Breast Cancer Market?

    The Americas is expected to lead the Male Breast Cancer Market.

    At what CAGR is the Male Breast Cancer Market projected to grow during the forecast period?

    The Male Breast Cancer Market is projected to grow at a 4.27% CAGR between 2024-2032.

    What are the key factors driving the Male Breast Cancer Market?

    Rising obese population and favorable healthcare expenditure are boosting market growth.

    Which factors may limit Male Breast Cancer Market growth?

    High treatment cost may limit market growth.

    What are the different strategies used by industry players to create a dominance in the Male Breast Cancer Market?

    Different strategies used by industry players to create a dominance in the Male Breast Cancer Market include strategic alliances, collaborations, expansions, and product launches.

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials